Symbol="IMAB"
AssetType="Common Stock"
Name="I-Mab"
Description="I-Mab, a clinical-stage biopharmaceutical company, discovers, develops and markets biologics to treat cancer and autoimmune disorders. The company is headquartered in Shanghai, the People's Republic of China."
CIK="1778016"
Exchange="NASDAQ"
Currency="USD"
Country="China"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="SUITE 802, WEST TOWER, OMNLVISION, 88 SHANGKE ROAD, PUDONG DISTRICT, SHANGHAI, CHINA"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="155332000"
EBITDA="-1859417984"
PERatio="None"
PEGRatio="None"
BookValue="29.48"
DividendPerShare="0"
DividendYield="0"
EPS="-3.58"
RevenuePerShareTTM="-3.057"
ProfitMargin="0"
OperatingMarginTTM="6.8"
ReturnOnAssetsTTM="-0.254"
ReturnOnEquityTTM="-0.662"
RevenueTTM="-253766000"
GrossProfitTTM="41594000"
DilutedEPSTTM="-3.58"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="-0.621"
AnalystTargetPrice="28.85"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="2.545"
PriceToBookRatio="0.587"
EVToRevenue="0.439"
EVToEBITDA="0.101"
Beta="0.931"
num_52WeekHigh="7.67"
num_52WeekLow="1.78"
num_50DayMovingAverage="2.718"
num_200DayMovingAverage="3.709"
SharesOutstanding="82623000"
DividendDate="None"
ExDividendDate="None"
symbol="IMAB"
open="1.90"
high="1.92"
low="1.85"
price="1.88"
volume="339094.00"
latest_trading_day="2023-08-25"
previous_close="1.89"
change="-0.01"
change_percent="-0.5291%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="92"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Sell Signal"
volume_analysis="Trending High"
value_analysis="Bullish Trend"
Aroon_change="FALSE"
Aroon_momentum="8"
Volume_recent_avg="329126"
Change_recent_avg="-0.01"
Delta_recent_avg="0.19"
Variance_recent_avg="0.1"
Change_ratio_recent_avg="-0.62"
RSI_change="FALSE"
ADX_change="FALSE"

event="aroon_milestone_negative_45"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="8"
Aroon_momentum_negative="92"
image_negative_thumbnail_id_1="109"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0067.jpeg"
image_negative_thumbnail_id_2="1124"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0157.jpeg"
image_neutral_thumbnail_id_1="587"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0012.jpeg"
image_neutral_thumbnail_id_2="583"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0016.jpeg"
image_positive_thumbnail_id_1="1016"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0178.jpeg"
image_positive_thumbnail_id_2="1014"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0176.jpeg"
image_professor_thumbnail_id_1="1194"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0028.jpeg"
image_professor_thumbnail_id_2="1176"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0010.jpeg"
